$BMRN
BIOMARIN PHARMACEUTICAL INC

2022 Q4 Form 10-Q Financial Statement

#000104847722000033 Filed on October 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $537.5M $505.3M
YoY Change 19.5% 23.63%
Cost Of Revenue $127.3M $116.3M
YoY Change 6.3% 12.32%
Gross Profit $410.2M $389.1M
YoY Change 24.29% 27.47%
Gross Profit Margin 76.32% 76.99%
Selling, General & Admin $245.7M $216.8M
YoY Change 12.95% 18.26%
% of Gross Profit 59.9% 55.73%
Research & Development $172.8M $157.8M
YoY Change 7.24% -0.03%
% of Gross Profit 42.11% 40.57%
Depreciation & Amortization $24.55M $24.80M
YoY Change -5.51% 117.56%
% of Gross Profit 5.98% 6.37%
Operating Expenses $434.7M $391.5M
YoY Change 9.8% 14.73%
Operating Profit -$24.50M -$2.417M
YoY Change -62.81% -95.46%
Interest Expense $5.084M $320.0K
YoY Change -776.06% -91.73%
% of Operating Profit
Other Income/Expense, Net $1.858M $193.0K
YoY Change 3103.45% -97.84%
Pretax Income -$17.56M -$1.904M
YoY Change -73.63% -95.88%
Income Tax -$17.31M $4.748M
% Of Pretax Income
Net Earnings -$249.0K -$6.652M
YoY Change -99.57% -81.77%
Net Earnings / Revenue -0.05% -1.32%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share $0.00 -$35.84K
COMMON SHARES
Basic Shares Outstanding 185.8M shares 185.5M shares
Diluted Shares Outstanding 185.6M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.292B $1.274B
YoY Change 27.39% 18.0%
Cash & Equivalents $724.5M $761.5M
Short-Term Investments $567.0M $512.3M
Other Short-Term Assets $104.5M $149.9M
YoY Change -5.36% 39.07%
Inventory $894.1M $839.5M
Prepaid Expenses
Receivables $461.3M $419.6M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.751B $2.683B
YoY Change 20.98% 16.06%
LONG-TERM ASSETS
Property, Plant & Equipment $1.073B $1.052B
YoY Change 3.66% 2.64%
Goodwill $196.2M $196.2M
YoY Change 0.0% 0.0%
Intangibles $338.6M $354.0M
YoY Change -12.89% -8.87%
Long-Term Investments $333.8M $372.3M
YoY Change -34.26% -20.21%
Other Assets $176.2M $1.607B
YoY Change 16.13% 1010.53%
Total Long-Term Assets $3.624B $3.581B
YoY Change -2.82% -2.31%
TOTAL ASSETS
Total Short-Term Assets $2.751B $2.683B
Total Long-Term Assets $3.624B $3.581B
Total Assets $6.375B $6.264B
YoY Change 6.19% 4.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $231.2M $207.2M
YoY Change 13.65% 1.89%
Accrued Expenses $317.8M $264.1M
YoY Change 18.21% 9.32%
Deferred Revenue $711.0K $415.0K
YoY Change -89.78% -95.7%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.287M
YoY Change
Total Short-Term Liabilities $588.9M $521.0M
YoY Change 9.09% 1.19%
LONG-TERM LIABILITIES
Long-Term Debt $1.083B $1.082B
YoY Change 0.38% 0.37%
Other Long-Term Liabilities $100.0M $92.47M
YoY Change 1.52% -10.33%
Total Long-Term Liabilities $100.0M $1.175B
YoY Change 1.52% 1038.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $588.9M $521.0M
Total Long-Term Liabilities $100.0M $1.175B
Total Liabilities $1.772B $1.696B
YoY Change 2.27% -0.92%
SHAREHOLDERS EQUITY
Retained Earnings -$789.2M -$788.9M
YoY Change -14.74% -9.09%
Common Stock $5.405B $5.336B
YoY Change 4.11% 3.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.603B $4.569B
YoY Change
Total Liabilities & Shareholders Equity $6.375B $6.264B
YoY Change 6.19% 4.79%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$249.0K -$6.652M
YoY Change -99.57% -81.77%
Depreciation, Depletion And Amortization $24.55M $24.80M
YoY Change -5.51% 117.56%
Cash From Operating Activities $6.786M $158.3M
YoY Change -39.3% 63.12%
INVESTING ACTIVITIES
Capital Expenditures $36.36M -$36.47M
YoY Change -181.97% 79.13%
Acquisitions
YoY Change
Other Investing Activities -$18.35M $13.07M
YoY Change 65.89% -113.14%
Cash From Investing Activities -$54.71M -$23.40M
YoY Change -1.28% -80.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.87M 7.541M
YoY Change -24.5% -831.43%
NET CHANGE
Cash From Operating Activities 6.786M 158.3M
Cash From Investing Activities -54.71M -23.40M
Cash From Financing Activities 10.87M 7.541M
Net Change In Cash -37.06M 142.5M
YoY Change 24.16% -698.12%
FREE CASH FLOW
Cash From Operating Activities $6.786M $158.3M
Capital Expenditures $36.36M -$36.47M
Free Cash Flow -$29.57M $194.8M
YoY Change -153.25% 65.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
415
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-26727
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
185848915 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
761515000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
587276000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
512253000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
426599000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
419622000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
373399000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
839460000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
776669000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
149851000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
110442000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
2682701000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2274385000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
372302000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
507793000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1051821000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1035461000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
354024000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388652000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
196199000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
196199000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1455205000 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1450161000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
151788000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152121000 usd
CY2022Q3 us-gaap Assets
Assets
6264040000 usd
CY2021Q4 us-gaap Assets
Assets
6004772000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
492717000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
498265000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28303000 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
48232000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
521020000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
546497000 usd
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1082033000 usd
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1079077000 usd
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
15167000 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
92473000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98361000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1695526000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1739102000 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185824253 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185824253 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
183912514 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
183912514 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
186000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
184000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5335853000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5191502000 usd
CY2022Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9325000 usd
CY2021Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9689000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
30749000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14432000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-788949000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930759000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4568514000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4265670000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6264040000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6004772000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
505344000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408742000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1558501000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1396465000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
116288000 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
103537000 usd
us-gaap Cost Of Revenue
CostOfRevenue
356379000 usd
us-gaap Cost Of Revenue
CostOfRevenue
350765000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157829000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157869000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
476855000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
467701000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
216816000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
183333000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
608270000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
541812000 usd
CY2022Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
16828000 usd
CY2021Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
17222000 usd
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
50935000 usd
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
52648000 usd
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
108000000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
507761000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
461961000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1384439000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1412926000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2417000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53219000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
174062000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16461000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4999000 usd
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1827000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
9324000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
8737000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4679000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
3870000 usd
us-gaap Interest Expense
InterestExpense
12344000 usd
us-gaap Interest Expense
InterestExpense
11491000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
193000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
9102000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-3908000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
10439000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1904000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46160000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
167134000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8776000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4748000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9666000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25324000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2594000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6652000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-36494000 usd
us-gaap Net Income Loss
NetIncomeLoss
141810000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6182000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185597000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
183214000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185009000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182616000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185597000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
183214000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192252000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182616000 shares
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5625000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25316000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
158127000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20196000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4499737000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
4236500000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4265670000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4100931000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4568514000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4261078000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
4568514000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4261078000 usd
us-gaap Net Income Loss
NetIncomeLoss
141810000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6182000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77416000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82053000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3089000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3114000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3741000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3279000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
149574000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
153372000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
108000000 usd
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-743000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12020000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
16075000 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1347000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2243000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
6254000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
700000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1317000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
53752000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-65513000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27419000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19125000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
8558000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-27029000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-12140000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
407000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2398000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7129000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3252000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
269000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
169116000 usd
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
38200000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
293356000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85271000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66840000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
477244000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
502112000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
457382000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
737144000 usd
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
110000000 usd
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
9910000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
8026000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
994000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
34681000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-310892000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
43866000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
32877000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
50696000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
44428000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
21054000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1635000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2492000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-401000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-29519000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14444000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-39000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-35000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
174239000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32015000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
587276000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1100000000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
649158000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
761515000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
617143000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
13425000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
15531000 usd
us-gaap Interest Paid Net
InterestPaidNet
6575000 usd
us-gaap Interest Paid Net
InterestPaidNet
6673000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-5240000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-7690000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
-224000 usd
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
9386000 usd
bmrn Number Of Commercial Products In Portfolio
NumberOfCommercialProductsInPortfolio
8 commercial_product
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
719000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements except for the transaction disclosed in Note 12 to these Condensed Consolidated Financial Statements.</span></div>
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1665775000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19720000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1646070000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
761515000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
512253000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
372302000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1523467000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2518000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1521668000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
587276000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
426599000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
507793000 usd
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
109480000 usd
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
80269000 usd
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
425505000 usd
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
415261000 usd
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
304475000 usd
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
281139000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149574000 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
839460000 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
776669000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1834220000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1756035000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
782399000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
720574000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1051821000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1035461000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
8700000 usd
us-gaap Depreciation
Depreciation
29900000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
11400000 usd
us-gaap Depreciation
Depreciation
35700000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
690334000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
677350000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
336310000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
288698000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
354024000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
388652000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
207165000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
199678000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
161112000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
204446000 usd
CY2022Q3 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
71653000 usd
CY2021Q4 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
47987000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
153372000 usd
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
14487000 usd
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
15215000 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
13075000 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6263000 usd
CY2022Q3 bmrn Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
9226000 usd
CY2021Q4 bmrn Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
10464000 usd
CY2022Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
7573000 usd
CY2021Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
1213000 usd
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
415000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6956000 usd
CY2022Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
8011000 usd
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6043000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
492717000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
498265000 usd
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
108000000 usd
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
61143000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
22775000 usd
CY2022Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
15301000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
7641000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
507761000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
461961000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1384439000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1412926000 usd
CY2022Q3 us-gaap Convertible Debt
ConvertibleDebt
1082033000 usd
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
1079077000 usd
CY2022Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1092701000 usd
CY2021Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1146204000 usd
CY2022Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
22687000 usd
CY2022Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
11344000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-934000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12277000 usd
CY2021Q3 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
11128000 usd
CY2021Q3 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
133000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-183000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11178000 usd
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
31823000 usd
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
19664000 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-4158000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
16317000 usd
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
20626000 usd
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
-4953000 usd
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
-799000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
26378000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
505344000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
408742000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1558501000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1396465000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
54663000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49026000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6652000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36494000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
141810000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6182000 usd
CY2022Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2021Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2806000 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6652000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36494000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
144616000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6182000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185597000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
183214000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
185009000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182616000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
185597000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
183214000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
192252000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182616000 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20556000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21055000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13313000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21055000 shares
bmrn Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
777600000 usd
CY2022Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
171500000 usd

Files In Submission

Name View Source Status
0001048477-22-000033-index-headers.html Edgar Link pending
0001048477-22-000033-index.html Edgar Link pending
0001048477-22-000033.txt Edgar Link pending
0001048477-22-000033-xbrl.zip Edgar Link pending
bmrn-20220930.htm Edgar Link pending
bmrn-20220930.xsd Edgar Link pending
bmrn-20220930_def.xml Edgar Link unprocessable
bmrn-20220930_htm.xml Edgar Link completed
bmrn-20220930_cal.xml Edgar Link unprocessable
bmrn-20220930_lab.xml Edgar Link unprocessable
exhibit-101.htm Edgar Link pending
exhibit311-30sep22x10q.htm Edgar Link pending
exhibit312-30sep22x10q.htm Edgar Link pending
exhibit321-30sep22x10q.htm Edgar Link pending
exhibit_102.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bmrn-20220930_pre.xml Edgar Link unprocessable